title: A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation.
abstract: OBJECTIVE
  To study the effect of subglottic secretions drainage on the incidence of ventilator-associated pneumonia (VAP) in patients receiving mechanical ventilation.
  
  
  METHODS
  A randomized clinical trial.
  
  
  METHODS
  A 12-bed general ICU.
  
  
  METHODS
  One hundred fifty patients with an expected duration of mechanical ventilation > 72 h were enrolled in the study.
  
  
  METHODS
  Patients were randomly assigned to receive either an endotracheal tube for intermittent subglottic secretions drainage or a standard endotracheal tube.
  
  
  METHODS
  Incidence of VAP, duration of mechanical ventilation, length of ICU stay, length of hospital stay, and mortality.
  
  
  RESULTS
  Seventy-five patients were randomized to subglottic secretion drainage, and 75 patients were randomized to the control group. The two groups were similar at the time of randomization with respect to demographic characteristics and severity of illness. VAP was seen in 3 patients (4%) receiving suction secretion drainage and in 12 patients (16%) in the control group (relative risk, 0.22; 95% confidence interval, 0.06 to 0.81; p = 0.014). The other outcome measures were not significantly different between the two groups.
  
  
  CONCLUSIONS
  Intermittent subglottic secretion drainage reduces the incidence of VAP in patients receiving mechanical ventilation.
authors.affiliation: Department of Medical Microbiology, Bosch Medicentrum, 's-Hertogenbosch, The Netherlands. k.sulders@boschmedicentrum.nl
authors.forename: Kees
authors.initials: K
authors.lastname: Smulders
authors.forename: Hans
authors.initials: H
authors.lastname: van der Hoeven
authors.forename: Ineke
authors.initials: I
authors.lastname: Weers-Pothoff
authors.forename: Christina
authors.initials: C
authors.lastname: Vandenbroucke-Grauls
mesh_terms: D000368:Aged; D004322:Drainage; D005260:Female; D006801:Humans; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000517:prevention & control*; D012121:Respiration, Artificial; D014132:Trachea / Q000382:microbiology